First-in-class SIK2 inhibitor enters Phase I trial
Nimbus Therapeutics has dosed the first subjects in its Phase I clinical trial of NDI-225673, a highly selective inhibitor of salt-inducible kinase 2 (SIK2) for the potential treatment of immune-mediated inflammatory diseases.
The Phase I trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of NDI-225673 in healthy volunteers.
Salt-inducible kinases (SIKs) comprise three closely related isoforms (SIK1, SIK2, and SIK3). SIK2 regulates transcriptional programmes involved in inflammatory responses and their resolution, particularly in myeloid cells such as macrophages.
In preclinical studies, selective SIK2 inhibition suppressed a broad set of key inflammatory drivers, including TNFα, IL-6, IL-23, and IL-1β, many of which are validated targets of approved biologics for inflammatory diseases. Additionally, selective SIK2 inhibition increased IL-10 and tissue-repair mediators, including amphiregulin (AREG) and thrombospondin-1 (THBS1), supporting its potential to combine broad anti-inflammatory activity with resolution and tissue repair.
In preclinical studies, NDI-225673 demonstrated potent nanomolar cellular activity and high selectivity for SIK2, supporting its potential to minimise potential liabilities associated with inhibition of other SIK isoforms.
“Many patients with immune-mediated inflammatory diseases, such as ulcerative colitis and rheumatoid arthritis, do not reach durable remission on current therapies,” said Peter Tummino, President of Research and Development at Nimbus. “Our goal with selective SIK2 inhibition is to go beyond suppressing individual inflammatory cytokines by engaging biological pathways that regulate inflammation and tissue repair. NDI-225673 represents years of research to achieve a high degree of SIK isoform selectivity, and this Phase I study gives us the opportunity to begin testing the SIK2 hypothesis directly in humans.”
Nimbus Therapeutics brings together structure-based drug discovery and advanced computational chemistry with AI- and machine learning-enabled predictive modelling. Nimbus’ pipeline also includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase I/II development for microsatellite instability-high (MSI-H) solid tumours.
